All In Biotech

Drug Trial Radar · NCT07829614

F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus

Phase Ib Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Immunogenicity of F182112 in Patients With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigational drug is an injectable recombinant humanized anti-BCMA/CD3 bispecific antibody (code: F182112) that can simultaneously target the immune effector cell antigen CD3 and the antigen BCMA. Through a dual-targeting mechanism, it aims to guide the body's own immune system to target and kill B cells and plasma cells that overexpress BCMA.Based on the application of B cell depletion strategies in the treatment of autoimmune diseases, as well as the exploration of similar drugs in autoimmune diseases, we speculate that F182112 is also effective for autoimmune diseases. Therefore, we plan to carry out clinical research of F182112 in patients with systemic lupus erythematosus, with the aim of bringing more treatment options to patients.

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • F182112Drug

    F182112 Dose Escalation and Dose Expansion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Incidence of Adverse Events (AE), Serious Adverse Events (SAE)Time frame: During the period of dose-limiting toxicity observation (within 28 days after the first administration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.